Biomet U.K. facility cited for design transfer deficiencies in FDA warning letter.
This article was originally published in The Gray Sheet
Executive Summary
BIOMET U.K. PLANT DESIGN TRANSFER DEFICIENCIES CITED BY FDA in a Nov. 1 warning letter to the Bridgen, U.K. facility. Stemming from a July 29-31 inspection, the two-page warning letter says that Biomet failed "to establish and implement specification control measures to assure that the design basis for the device and packaging is correctly translated into approved specifications." The citations relate to Biomet's production of Brooker-Wills orthopedic cancellous screws.
You may also be interested in...
Biomet Oxford Knee PMA Inspection In UK Results In FDA Warning Letter
Biomet says it will consider alternative production sites for its Stanmore hip, Copeland shoulder and Oxford knee implantable devices if the company and FDA are unable to resolve sterilization and validation issues in a timely fashion at a UK facility identified by the agency in a Feb. 19 warning letter
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”